SOX2-specific adaptive immunity and response to immunotherapy in non-small cell lung cancer

OncoImmunology

Volumn 2, Issue 7, 2013, Pages

  Dhodapkar, Kavita M ^a,c   Gettinger, Scott N ^b,c   Das, Rituparna ^b   Zebroski, Henry ^d   Dhodapkar, Madhav V ^b,c  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b YALE UNIVERSITY   (United States)

^c YALE CANCER CENTER   (United States)

^d ROCKEFELLER UNIVERSITY   (United States)

Author keywords

Checkpoint blockade; Embryonal stem cells; Immunotherapy; Lung cancer; Programmed death 1; Sox2

Indexed keywords

NIVOLUMAB; NY ESO 1 ANTIGEN; TRANSCRIPTION FACTOR SOX2;

ADAPTIVE IMMUNITY; ANTIGEN DETECTION; ARTICLE; CANCER IMMUNOTHERAPY; CANCER PATIENT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CYTOKINE RESPONSE; DISEASE ASSOCIATION; HUMAN; HUMORAL IMMUNITY; IN VIVO STUDY; LUNG NON SMALL CELL CANCER; PERIPHERAL BLOOD MONONUCLEAR CELL; REMISSION;

EID: 84886944580     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.25205     Document Type: Article

References (23)

1. DuPage M, Cheung AF, Mazumdar C, Winslow MM, Bronson R, Schmidt LM, et al. Endogenous T cell responses to antigens expressed in lung adenocarcinomas delay malignant tumor progression. Cancer Cell 2011; 19:72-85; PMID:21251614; http://dx.doi. org/10.1016/j.ccr.2010.11.011
2. Ruffini E, Asioli S, Filosso PL, Lyberis P, Bruna MC, MacrÍ L, et al.Clinical significance of tumor-infiltrating lymphocytes in lung neoplasms.Ann Thorac Surg 2009; 87:365-71, discussion 371-2; PMID:19161739; http://dx.doi.org/10.1016/j.athoracsur.2008.10.067
3. Suzuki K, Kadota K, Sima CS, Nitadori J, Rusch VW, Travis WD, et al.Clinical impact of immune microenvironment in stage I lung adenocarcinoma: tumor interleukin- 12 receptor ß2 (IL-12Rß2), IL-7R, and stromal FoxP3/CD3 ratio are independent predictors of recurrence.J Clin Oncol 2013; 31:490-8; PMID:23269987; http://dx.doi.org/10.1200/JCO.2012.45.2052
4. Kawai O, Ishii G, Kubota K, Murata Y, Naito Y, Mizuno T, et al.Predominant infiltration of macrophages and CD8(+) T Cells in cancer nests is a significant predictor of survival in stage IV nonsmall cell lung cancer.Cancer 2008; 113:1387-95; PMID:18671239; http://dx.doi.org/10.1002/cncr.23712
5. Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, et al.Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.N Engl J Med 2012; 366:2455-65; PMID:22658128; http:// dx.doi.org/10.1056/NEJMoa1200694
6. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al.Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.N Engl J Med 2012; 366:2443-54; PMID:22658127; http://dx.doi.org/10.1056/NEJMoa1200690
7. Sznol M, Chen L.Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer.Clin Cancer Res 2013; 19:1021-34; PMID:23460533; http://dx.doi.org/10.1158/1078- 0432.CCR-12-2063
8. Boyer LA, Lee TI, Cole MF, Johnstone SE, Levine SS, Zucker JP, et al.Core transcriptional regulatory circuitry in human embryonic stem cells.Cell 2005; 122:947-56; PMID:16153702; http://dx.doi.org/10.1016/j.cell.2005.08.020
9. Bass AJ, Watanabe H, Mermel CH, Yu S, Perner S, Verhaak RG, et al.SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas.Nat Genet 2009; 41:1238-42; PMID:19801978; http://dx.doi.org/10.1038/ng.465
10. Hussenet T, du Manoir S.SOX2 in squamous cell carcinoma: amplifying a pleiotropic oncogene along carcinogenesis.Cell Cycle 2010; 9:1480-6; PMID:20372069; http://dx.doi.org/10.4161/cc.9.8.11203
11. McCaughan F, Pole JC, Bankier AT, Konfortov BA, Carroll B, Falzon M, et al.Progressive 3q amplification consistently targets SOX2 in preinvasive squamous lung cancer.Am J Respir Crit Care Med 2010; 182:83-91; PMID:20299530; http://dx.doi.org/10.1164/rccm.201001-0005OC
12. Nakatsugawa M, Takahashi A, Hirohashi Y, Torigoe T, Inoda S, Murase M, et al.SOX2 is overexpressed in stem-like cells of human lung adenocarcinoma and augments the tumorigenicity.Lab Invest 2011; 91:1796-804; PMID:21931300; http://dx.doi.org/10.1038/labinvest.2011.140
13. Xiang R, Liao D, Cheng T, Zhou H, Shi Q, Chuang TS, et al.Downregulation of transcription factor SOX2 in cancer stem cells suppresses growth and metastasis of lung cancer.Br J Cancer 2011; 104:1410-7; PMID:21468047; http://dx.doi.org/10.1038/bjc.2011.94
14. Spisek R, Kukreja A, Chen LC, Matthews P, Mazumder A, Vesole D, et al.Frequent and specific immunity to the embryonal stem cell-associated antigen SOX2 in patients with monoclonal gammopathy.J Exp Med 2007; 204:831-40; PMID:17389240; http://dx.doi.org/10.1084/jem.20062387
15. Dhodapkar MV, Dhodapkar KM.Vaccines targeting cancer stem cells: are they within reach?.Cancer J 2011; 17:397-402; PMID:21952290; http://dx.doi.org/10.1097/PPO.0b013e318233e730
16. GÜre AO, Stockert E, Scanlan MJ, Keresztes RS, JÄger D, Altorki NK, et al.Serological identification of embryonic neural proteins as highly immunogenic tumor antigens in small cell lung cancer.Proc Natl Acad Sci U S A 2000; 97:4198-203; PMID:10760287; http://dx.doi.org/10.1073/pnas.97.8.4198
17. Chen S, Xu Y, Chen Y, Li X, Mou W, Wang L, et al.SOX2 gene regulates the transcriptional network of oncogenes and affects tumorigenesis of human lung cancer cells.PLoS One 2012; 7:e36326; PMID:22615765; http://dx.doi.org/10.1371/journal.pone.0036326
18. Velcheti V, Schalper K, Yao X, Cheng H, Kocoglu M, Dhodapkar K, et al.High SOX2 Levels Predict Better Outcome in Non-Small Cell Lung Carcinomas.PLoS One 2013; 8:e61427; PMID:23620753; http://dx.doi.org/10.1371/journal.pone.0061427
19. Jungbluth AA, Chen YT, Stockert E, Busam KJ, Kolb D, Iversen K, et al.Immunohistochemical analysis of NY-ESO-1 antigen expression in normal and malignant human tissues.Int J Cancer 2001; 92:856-60; PMID:11351307; http://dx.doi.org/10.1002/ijc.1282
20. Yuan J, Adamow M, Ginsberg BA, Rasalan TS, Ritter E, Gallardo HF, et al.Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab.Proc Natl Acad Sci U S A 2011; 108:16723-8; PMID:21933959; http://dx.doi.org/10.1073/pnas.1110814108
21. van Elsas A, Sutmuller RP, Hurwitz AA, Ziskin J, Villasenor J, Medema JP, et al.Elucidating the autoimmune and antitumor effector mechanisms of a treatment based on cytotoxic T lymphocyte antigen-4 blockade in combination with a B16 melanoma vaccine: comparison of prophylaxis and therapy.J Exp Med 2001; 194:481-9; PMID:11514604; http://dx.doi.org/10.1084/jem.194.4.481
22. Taube JM, Anders RA, Young GD, Xu H, Sharma R, McMiller TL, et al.Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape.Sci Transl Med 2012; 4:27ra37; PMID:22461641; http://dx.doi.org/10.1126/scitranslmed.3003689
23. Dhodapkar KM, Feldman D, Matthews P, Radfar S, Pickering R, Turkula S, et al.Natural immunity to pluripotency antigen OCT4 in humans.Proc Natl Acad Sci U S A 2010; 107:8718-23; PMID:20404147; http://dx.doi.org/10.1073/pnas.0915086107